Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (972)	6/1/2004 12:54:33 PM
From: Jibacoa	Respond to of 1005

POZN trading down $4.08, or 41.1%, and volume more than 6.2M after it received a not-approvable letter from the FDA for its MT 100. In the letter, the FDA cited a lack of superiority of MT 100 over naproxen for sustained pain relief, which was the primary end point. It also raised issues about the risk of tardive dyskinesia, which is associated with metoclopramide, a component of MT 100. bigcharts.marketwatch.com Bernard